Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.61 |
| ▸ | JAK1 | P23458 | 8/20 | 0.61 |
| ▸ | TYK2 | P29597 | 8/20 | 0.61 |
| ▸ | JAK3 | P52333 | 7/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13606501 | 0.85 | JAK2 (0.65) | JAK2JAK1TYK2JAK3IKBKE | |
| SCHEMBL5458391 | 0.83 | JAK2 (0.75) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL5463494 | 0.77 | JAK2 (0.63) | JAK2JAK1TYK2JAK3TBK1 | |
| SCHEMBL13606546 | 0.76 | JAK2 (0.70) | JAK2JAK1TYK2JAK3TBK1 | |
| SCHEMBL13606556 | 0.76 | JAK2 (1.00) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL14518735 | 0.75 | JAK2 (0.56) | JAK2JAK1TYK2JAK3IKBKE | |
| SCHEMBL13613575 | 0.74 | JAK2 (0.47) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613576 | 0.74 | JAK2 (0.47) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613449 | 0.74 | JAK2 (0.66) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613453 | 0.72 | JAK2 (0.62) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | JAK2 1101/4885JAK1 1726/4885TYK2 2825/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | JAK2 1101/4885JAK1 1726/4885TYK2 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.